UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average bur	den
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe response															
1. Name and Address of Reporting Person SHERWIN STEPHEN A (Last) (First) (Middle) CELL GENESYS, INC.,, 500 FORBES BOULEVARD (Street)				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL] 3. Date of Earliest Transaction (Month/Day/Year) 06/03/2004 4. If Amendment, Date Original Filed(Month/Day/Year)							S. Relationship of Reporting Person(s) to Issuer					
)	
										X					,	
SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)											lired, Disposed of, or Beneficially Owned					
			2A. De	amad		Transaction					•				7. Nature	
1.Title of Security (Instr. 3) 2. Transact Date (Month/Date)			Execut any	tion Date,	if Co (In	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(D) Owr Tran	ned Followin saction(s)	ecurities Beneficially ng Reported		Ownership Form:	of Indirect Beneficial	
				(Month	h/Day/Yea		Code \	V Am	Amount (A) or (D)		(Inst	nstr. 3 and 4)		OI (I	r Indirect (In	Ownership (Instr. 4)
Reminder:									who resp rm are n					form displa		1474 (9-02)
Reminder:			Table II				in t a co Acquired, I	this for urrent Dispose	rm are n ly valid (ed of, or I	ot req OMB (Benefic	uired to control n	respond u umber.				14/4 (3-02)
1. Title of Derivative Security (Instr. 3)		*****	3A. Deemed Execution Date, if	4. Transact Code	5. Nu of Deriv	mber ative ities ired sed	in t a c	this for urrent Dispose is, conv xercisal n Date	rm are n ly valid (ed of, or I rertible so ble and	ot req OMB (Benefic	uired to control n cially Owr	respond u umber. ned nd Amount lying	8. Price of Derivative Security		f 10. Ownersh Form of Derivativ Security: Direct (I or Indire	in 11. Natur of Indirect Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact Code	ion of Derive Secur Acque (A) of Disposof (D) (Instr	mber ative ities ired sed	in t a control Acquired, I ants, option 6. Date Ex Expiration	this for urrent! Dispose is, conv xercisal in Date Day/Yea	rm are n ly valid (ed of, or I rertible so ble and	ot req OMB of Benefic ecuriti	cially Ownes) 7. Title ar of Underl Securities	respond u umber. ned nd Amount lying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivativ Security: Direct (I or Indire	11. Natur of Indired Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
SHERWIN STEPHEN A CELL GENESYS, INC., 500 FORBES BOULEVARD SOUTH SAN FRANCISCO, CA 94080	X				

Signatures

James H. Welch (Attorney-In-Fact)	06/04/2004
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Fully vested on 6/10/04.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \textit{see} \ Instruction 6 for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.